COPD

The majority of patients with chronic obstructive pulmonary disease (COPD) do not receive positive airway pressure (PAP) therapy despite its effectiveness in reducing hospitalizations, according to research.

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

Patients with chronic obstructive pulmonary disease (COPD) often experience chronic pain symptoms, including low physical activity, depression, and hyperinflation, that impact their everyday lives.

Those with chronic obstructive pulmonary disease (COPD) may be more likely to suffer from a heart attack or stroke following an acute exacerbation if they have a history or at risk of cardiovascular disease (CVD).

While treatments prescribed for people with chronic pulmonary disease (COPD) and asthma—COPD overlap syndrome (ACOS) are similar, there is a need for a clearer therapeutic approach for patients with ACOS, according to a new study.

With more women dying annually from chronic obstructive pulmonary disease (COPD) than men since 2000, researchers have examined trends in COPD hospitalization and in-hospital mortality, evaluating for differences by sex and race. They presented their research at the American Thoracic Society 2017 International Conference.

Patients with chronic obstructive pulmonary disease (COPD) may dismiss medical advice if the benefit of the treatment is insignificant in comparison to the burden.

Patients with comorbid depression and chronic obstructive pulmonary disease (COPD) have low rates of adherence to their COPD management medications, putting them at increased risk of emergency department visits and hospitalizations.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories include an announcement that CMS will take Social Security numbers off Medicare cards; a national plan to combat chronic obstructive pulmonary disease was released; and a nutrition advocacy group calls on FDA to stick with the schedule for a new nutrition facts label.

The National Heart, Lung, and Blood Institute has released the first-ever COPD National Action Plan, which is aimed at ending the illness.

A JAMA study has found that patients with chronic obstructive pulmonary disease (COPD) who received noninvasive ventilation in addition to home oxygen therapy went longer without being readmitted to the hospital or dying than those who received only home oxygen therapy.

A panel at the Pharmacy Quality Alliance talks about how to take patient input and turn it into meaningful measurement.

An analysis of discontinuation in randomized controlled trials for chronic obstructive pulmonary disease (COPD) has determined the main factors causing patients to drop out of clinical trials. The results were published in the International Journal of COPD.

Getting smokers to quit smoking sometimes requires medical intervention, such as varenicline and bupropion; however, there have been concerns about the safety of these smoking cessation treatments in smokers with chronic obstructive pulmonary disease.

Short-term use of high-flow nasal tubes can help patients experiencing exacerbations of their chronic obstructive pulmonary disease, according to a study in Respirology.

A study in Journal of Medical Internet Research sought to discover how technologies could encourage daily walking in this population. The researchers developed 3 prototype apps using different persuasive technology design principles: dialogue support, primary task support, and social support.

In primary care, nurse practitioners and physician assistants do not necessarily order more ancillary services, or more costly services among alternatives, than physicians.

High-cost patients are only modestly concentrated in specific hospitals and healthcare markets.

The European Respiratory Society and the American Thoracic Society have conducted a comprehensive review of evidence of managing exacerbations of chronic obstructive pulmonary disease in order to create a guideline of clinical recommendations.

A new collaboration between the Duke Clinical Research Institute, Duke University’s MURDOCK Study, and Boehringer Ingelheim Pharmaceuticals Inc will try to better understand how chronic obstructive pulmonary disease progresses in the real world.

Patients with chronic obstructive pulmonary disease see benefits from physical activity (PA); however, there are several barriers that limit participation in PA in a primary care setting.

Palliative care can help alleviate the suffering and symptoms that go along with serious disease, making it an important component when caring for complex, high-need patients, said Allison Silvers, vice president of payment and policy at the Center to Advance Palliative Care.